← Eichor
Study identifier: NCT06136650 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic Neoplasms  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 3
Planned participants1314
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (329)

The University of Arizona Cancer Center - North Campus ( Site 0073)Tucson, Arizona, United StatesRecruiting
UCLA Hematology/Oncology - Santa Monica ( Site 0044)Los Angeles, California, United StatesRecruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)Orange, California, United StatesRecruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center (0120)Orange, California, United StatesRecruiting
Stanford Cancer Center ( Site 0036)Palo Alto, California, United StatesRecruiting
Emad Ibrahim,MD,INC. ( Site 0012)Redlands, California, United StatesCompleted
Kaiser Permanente Riverside Medical Center ( Site 0099)Riverside, California, United StatesRecruiting
University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 0114)Sacramento, California, United StatesRecruiting
San Francisco VA Health Care System ( Site 0093)San Francisco, California, United StatesRecruiting
Kaiser Permanente-Kaiser Permanente, Vallejo Medical Center, Adult Oncology ( Site 0101)Vallejo, California, United StatesRecruiting
University of Colorado Anschutz Medical Campus ( Site 0046)Aurora, Colorado, United StatesRecruiting
UCHealth Highlands Ranch Hospital ( Site 0111)Highlands Ranch, Colorado, United StatesRecruiting

+ 317 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06136650